Stribild® (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate): A New Paradigm for HIV-1 Treatment

被引:0
作者
Manzardo, Christian [1 ]
Gatell, Jose M. [1 ]
机构
[1] Univ Barcelona, Hosp Clin IDIBAPS, Infect Dis & AIDS Unit, Barcelona, Spain
关键词
HIV-1; HAART; Elvitegravir; Cobicistat; Single tablet treatment; Naive patients; Treatment-experienced patients; SINGLE-TABLET REGIMENS; CO-FORMULATED ELVITEGRAVIR; ONCE-DAILY ELVITEGRAVIR; TWICE-DAILY RALTEGRAVIR; INITIAL TREATMENT; DOUBLE-BLIND; INFECTION ANALYSIS; INTEGRASE; PHASE-3; COBICISTAT;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Stribild (R) (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) is a new single-tablet, fixed-dose formulation approved by both the US Food and Drug Administration and the European Medicine Agency as antiretroviral therapy. It is the first once-a-day therapy option containing an integrase inhibitor and cobicistat, a novel pharmacokinetic boosting agent without activity on HIV. Stribild (R) has demonstrated non-inferior virological efficacy and a similar recovery of CD4(+) T-cells when compared to Atripla (R) (efavirenz/emtricitabine/tenofovir) and to ritonavir-boosted atazanavir plus emtricitabine/tenofovir in two large, phase III randomized clinical trials at 48, 96, and 144 weeks. These results are consistent in all CD4(+) and HIV RNA strata. Although well-tolerated, self-limiting nausea has been reported in more than 10% of patients in both trials. Cobicistat has clinically significant drug-drug interactions with drugs that are metabolized by the cytochrome P450 3A4 subfamily enzymes, and causes a minimal reversible decrease of the estimated glomerular filtration rate due to inhibition of molecular transporters of creatinine in kidney tubules. Elvitegravir primary resistance mutations associated with treatment failure often lead to cross-resistance to raltegravir.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 37 条
[1]   Single-tablet regimens in HIV: does it really make a difference? [J].
Aldir, Isabel ;
Horta, Ana ;
Serrado, Margarida .
CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (01) :89-97
[2]  
Clumeck N, 2013, J ACQUIR IMMUNE DEFI
[3]   Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection [J].
Cohen, Calvin ;
Elion, Richard ;
Ruane, Peter ;
Shamblaw, David ;
DeJesus, Edwin ;
Rashbaum, Bruce ;
Chuck, Steven L. ;
Yale, Kitty ;
Liu, Hui C. ;
Warren, David R. ;
Ramanathan, Srinivasan ;
Kearney, Brian P. .
AIDS, 2011, 25 (06) :F7-F12
[4]  
Deeks E, 2013, DRUGS
[5]   Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients [J].
DeJesus, Edwin ;
Berger, Daniel ;
Markowitz, Martin ;
Cohen, Calvin ;
Hawkins, Trevor ;
Ruane, Peter ;
Elion, Richard ;
Farthing, Charles ;
Zhong, Lijie ;
Cheng, Andrew K. ;
McColl, Dainian ;
Kearney, Brian P. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (01) :1-5
[6]   Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial [J].
DeJesus, Edwin ;
Rockstroh, Juergen K. ;
Henry, Keith ;
Molina, Jean-Michel ;
Gathe, Joseph ;
Ramanathan, Srinivasan ;
Wei, Xuelian ;
Yale, Kitty ;
Szwarcberg, Javier ;
White, Kirsten ;
Cheng, Andrew K. ;
Kearney, Brian P. .
LANCET, 2012, 379 (9835) :2429-2438
[7]  
EACS European AIDS Clinical Society, GUID VERS 7
[8]  
Elion R, 2013, JAIDS-J ACQ IMM DEF, V63, P494, DOI 10.1097/QAI.0b013e318298469c
[9]   Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial [J].
Eron, Joseph J., Jr. ;
Rockstroh, Juergen K. ;
Reynes, Jacques ;
Andrade-Villanueva, Jaime ;
Ramalho-Madruga, Jose Valdez ;
Bekker, Linda-Gail ;
Young, Benjamin ;
Katlama, Christine ;
Maria Gatell-Artigas, Jose ;
Arribas, Jose R. ;
Nelson, Mark ;
Campbell, Havilland ;
Zhao, Jing ;
Rodgers, Anthony J. ;
Rizk, Matthew L. ;
Wenning, Larissa ;
Miller, Michael D. ;
Hazuda, Daria ;
DiNubile, Mark J. ;
Leavitt, Randi ;
Isaacs, Robin ;
Robertson, Michael N. ;
Sklar, Peter ;
Nguyen, Bach-Yen .
LANCET INFECTIOUS DISEASES, 2011, 11 (12) :907-915
[10]  
European Medicines Agency, 2013, STRIB 150 MG 150 MG